Jehn, U.;                     Siam, S.;                     Wiening, V.;                     Pavenstädt, H.;                     Reuter, S.    
        Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses 2022, 14, 1005.
    https://doi.org/10.3390/v14051005
    AMA Style
    
                                Jehn U,                                 Siam S,                                 Wiening V,                                 Pavenstädt H,                                 Reuter S.        
                Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses. 2022; 14(5):1005.
        https://doi.org/10.3390/v14051005
    
    Chicago/Turabian Style
    
                                Jehn, Ulrich,                                 Sami Siam,                                 Vanessa Wiening,                                 Hermann Pavenstädt,                                 and Stefan Reuter.        
                2022. "Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection" Viruses 14, no. 5: 1005.
        https://doi.org/10.3390/v14051005
    
    APA Style
    
                                Jehn, U.,                                 Siam, S.,                                 Wiening, V.,                                 Pavenstädt, H.,                                 & Reuter, S.        
        
        (2022). Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses, 14(5), 1005.
        https://doi.org/10.3390/v14051005